Report top-line data for the IMGN632 pivotal cohort
Deadline passed; outcome being checked
- Announced
- 11 Jan 2021
- Due
- 11 Jul 2022
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ENROLLMENT AND TOP-LINE DATA 12-18 MONTHS”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +51 days
- 2 versions
-
Version 1 · original · stated 11 Jan 2021
Deadline 11 Jul 2022 (“12-18 MONTHS”)
-
Version 2 · stated 12 Feb 2021
Deadline 31 Aug 2022 (“12 to 18 months”)
“Enroll patients in the pivotal cohort of the 801 Phase 1/2 study of IMGN632 in frontline BPDCN patients and generate top-line data in 12 to 18 months.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- IMGN632 pivotal cohort top-line data
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you ImmunoGen, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C855654-021744 · Corrections policy